Cocrystal Pharma, Inc. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand Cocrystal Pharma’s performance this year. My goal is to turn complex filing data into clear information so you can decide if this company fits your investment goals.

1. What does the company do?

Cocrystal is a biotech company in the testing phase. They don’t sell medicine in pharmacies yet. Instead, they use a specialized platform to design antiviral drugs for the flu, norovirus, and COVID-19.

Their biggest win this year was CDI-988, an oral treatment for norovirus. They finished Phase 1 safety testing, which showed the drug was safe for healthy volunteers. As of February 2026, they began a human challenge study at Emory University. This is a major step, as they are now testing if the drug actually works in a controlled environment.

2. Financial performance

Cocrystal is in the "spending" phase typical of early-stage biotech. For the year ending December 31, 2025, they earned about $0.1 million from old licensing deals. Meanwhile, they spent $12.4 million on research and development. Their total loss for the year was roughly $17.8 million. With a market value of about $11.6 million, this is a small, high-stakes research company, not a business with steady product sales.

3. Major wins and challenges

The company’s main strength is its intellectual property. They hold over 50 patents and applications, with protections lasting into the early 2040s. This gives them a long window to potentially bring products to market.

The challenge is the competition. They are up against pharmaceutical giants with annual research budgets over $10 billion. In the flu market, they are developing new treatments to fight drug-resistant strains. In the norovirus space, they are racing to address a $10.6 billion annual burden on the U.S. healthcare system. However, they lack the massive sales teams and infrastructure of their larger rivals.

4. Financial health

The company relies on selling stock to pay for operations. They held about $14.2 million in cash as of their last filing. They often use "At-the-Market" offerings to sell shares directly to the public. Be aware that this strategy leads to more shares being issued, which reduces your ownership percentage in the company.

5. Key risks

The company’s value depends almost entirely on the success of its clinical trials. If their drugs fail to show results, the company may run out of money. Additionally, their Hepatitis C drug has been inactive since 2017. They are looking for a partner to fund further testing, but without a deal, this asset provides no value to shareholders.

6. Future outlook

The company’s future depends on the results from the Emory University norovirus study. Positive results could lead to a partnership or buyout. Negative results would likely force the company to sell more shares to keep the lights on. Until they get FDA approval, this remains a high-risk, speculative investment that requires you to watch their spending closely.

Final Thought for Investors: When looking at a company like Cocrystal, ask yourself if you are comfortable with "binary" outcomes—where the stock price is tied directly to the success or failure of a specific clinical trial. If you prefer steady growth, this may not be the right fit. If you are interested in the potential of early-stage biotech, keep a close eye on their cash burn rate and the upcoming results from their Emory University study.